pt-112

Neoplasms by Site

Promontory Therapeutics Inc.Phase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

9 Active assets in the Neoplasms by Site cohort.

Asset / Sponsor	Phase	Rating
Relatlimab Bristol-Myers Squibb	Phase 2	BB
Pralsetinib, trans- Seoul National University Bundang Hospital	Phase 3	BB
pf-08634404 Pfizer	Phase 3	B
Catequentinib Sun Yat-sen University	Phase 2	B
PSMA-HBED-CC ALF-18 Alessandro D'Agnolo	Phase 2	B

View all 15 →

Same molecule, other indications

pt-112 is also rated in:

CRPCDormant

CCC

Indicative ·

53 / 100

mCRPCDormant

CCC

Indicative ·

53 / 100

Metastatic Castrate-resistant Prostate CancerDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.